Our Company

Meet the Leadership Team

Marzio Pozzuoli

Chief Executive Officer
Toronto, Canada

Phil Levy, P. Eng.

Chief Technology Officer

Toronto, Canada

Dr. Keith Thompson, MD, FCFP

Chief Medical Officer

Toronto, Canada

Dr. Naresh Vempala, Ph.D.

Director of Research
Toronto, Canada

Dr. Roberto Liddi, Ph.D.

VP of Regulatory Affairs and Compliance
Oxford,
       United Kingdom       

Dr. Aileen Zhou  Ph.D., BASc

Director of Regulatory Affairs 

Toronto, Canada

Dr. Paul Zheng, Ph.D.

Chief Researcher

Toronto, Canada

Chris Lin

Chief Marketing Officer

Toronto, Canada

Roy Dalton, CPA, CA

Chief Financial Officer

Toronto, Canada

Michael Keefe

VP of Global Sales

Toronto, Canada

Dr. Hu Jun, PhD.

General Manager
(China Region)
Hangzhou, China

Prof. John Cockcroft

Scientific Advisor
New York, United States

Dr. Kang Lee, Ph.D.

Chief Science Officer Emeritus (2015-2021) Toronto, Canada

Marzio Pozzuoli

Chief Executive Officer

Marzio is an experienced and passionate technology entrepreneur with over 30 years of product development experience. Prior to NuraLogix, Marzio founded RuggedCom, a communications networking company, which he took from startup to acquisition and was named the CVCA Entrepreneur of The Year for 2013.

Phil Levy, P. Eng.

Chief Technology Officer

Phil is the CTO at NuraLogix and is a veteran leader of technology product development. He brings over 25 years of direct experience with diverse, high-performance R&D teams creating breakthrough technologies.

Dr. Thompson obtained his Doctorate, Doctor of Medicine, from the University of Western Ontario. He is Fellowship Canadian College Family Practice and Adjunct Faculty Dept Family Medicine UWO, involved in Virtual Care research. He is BCMAS (Board Certified Medical Affairs Specialist) and is working Group Lead for both IEEE SA and WONCA e-Health.

Dr. Naresh Vempala, Ph.D.

Director of Research

Dr. Vempala has a Ph.D. in cognitive science minoring in AI, an M.S. in computer science from the Center for Advanced Computer Studies, University of Louisiana at Lafayette, and an M.S. in civil engineering from Mississippi State University. He has over 20 years of experience in industry and academia.

Dr. Roberto Liddi, Ph.D.

VP of Regulatory Affairs and Compliance

Experienced regulatory professional with a demonstrated history of working in the medical device manufacturing industry. Skilled in U.S. Food and Drug Administration (FDA) Regulations, Regulatory Strategy, Corrective and Preventive Action (CAPA), Quality Auditing, Risk Management and CE marking. He has experience in a variety of medical device industries, spanning from orthopaedic device, to neurosurgical and3D printed implantable devices, IVD and Software as Medical Device. Strong healthcare services professional with a Doctorate in Biological Sciences focused in Human Biology and Immunolgy from Università degli Studi di Bari. Previous member of Advisory Group to the European Commission and current Chair of the Digital Health Group – ABHI. Caldicott Guardian and DPO listed. Member of the NHS NIHR D4D Committee

Dr. Aileen Zhou, PhD, BASc

Director of Regulatory Affairs

 

Aileen brings over a decade of experience in regulatory affairs working with innovative medical devices in domestic and global markets. Prior to joining NuraLogix, Aileen held several regulatory leadership positions, including Senior Manager, Regulatory Affairs at Centre for Commercialization of Regenerative Medicine (CCRM) and Project Manager, Regulatory Affairs at Synaptive Medical, a global medical device and technology company. In these roles, Aileen provided pivotal regulatory leadership throughout the product lifecycle and played a leading role in regulatory filings and product registrations in the U.S., Canada, EU, Australia, and other international markets. Prior to that, Aileen held several positions in scientific and regulatory affairs at Induce Biologics, an innovative tissue engineering company. During her tenure, Aileen single-handedly built up the entire regulatory asset and led several successful interactions with Health Canada and the U.S. FDA.

Aileen earned a PhD with a focus in biotechnology as an NSERC scholar and a Bachelor of Applied Science in biomedical engineering, both from the University of Toronto. She is an active member and contributing author of Regulatory Affairs Professional Society.

Dr. Paul Zheng, PhD.

Chief Researcher

Dr. Pu Zheng (Paul) is the Co-founder and Senior Researcher of NuraLogix. He holds a PhD. degree in emotional psychology and has over 8 years of experience in designing and conducting behavioural and neuroimaging psychology experiments.

Chris Lin

Chief Marketing Officer

Chris Lin joined NuraLogix in 2018 as CMO, he leads the company’s brand, product strategy, go-to-market strategy and demand generation. Chris held sales and marketing leadership positions at GE, SAP, Microsoft, IBM, Dell, and Lenovo.

Roy Dalton, CPA, CA

Chief Financial Officer

Roy Dalton joined Nuralogix in 2023 and is the company’s Chief Financial Officer. Mr. Dalton brings to the company more than 30 years of financial experience with both public and private hardware and software technology companies. Mr. Dalton was the CFO at RuggedCom, a communications networking company, from 2004 until 2012, until its acquisition by Siemens.

Michael Keefe

VP of Global Sales

Michael Keefe is the Vice President, Global Sales at NuraLogix. Michael brings more than 25 years of sales, strategy and product innovation experience to NuraLogix, previously working with clients including Akzo Nobel/Organon (Merck), Johns Hopkins, US Army TATRC and MediResource to expand sales and bring new products to market.

Dr. Hu Jun, PhD.

General Manager (China Region)

Dr. Hu is the GM of our WOFE, NuraLogix (Hangzhou) Artificial Intelligence Co., Ltd.. He holds a PhD in mechanical engineering and has over 20 years of technical, sales and management experience. Prior NuraLogix, Dr. Hu was GM of RuggedCom China.

Prof. John Cockcroft

Scientific Advisor

Professor Cockcroft is visiting Professor in the Dept of Advanced Cardiology at Columbia University Medical Center, New York where he is researching haemodynamics in patients with left ventricular assist devices (LVAD’s) in terms of the vascular complications seen in this group in order to improve their cardiovascular outcomes. He has published over 350 peer-reviewed articles in the field of hypertension and cardiovascular disease.

Dr. Kang Lee, PhD.

Chief Science Officer Emeritus (2015-2021)

Dr. Lee was one of the three Co-founders of NuraLogix. He served as Chief Science Officer from the company’s founding in 2015 until September 1st of 2021. During his time at NuraLogix Dr. Lee helped pioneer Transdermal Optical Imaging (TOI™) and its use in health and wellness applications across multiple industries. He co-authored 11 patents along with numerous scientific papers and publications on the science of TOI and its many uses for healthcare.

Dr. Lee is a professor and Tier 1 Canada Research Chair in developmental neuroscience at the University of Toronto.